Roth Michael, Linkowski Marissa, Tarim John, Piperdi Sajida, Sowers Rebecca, Geller David, Gill Jonathan, Gorlick Richard
Division of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York.
Cancer. 2014 Feb 15;120(4):548-54. doi: 10.1002/cncr.28461. Epub 2013 Oct 25.
Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma.
Immunohistochemistry was performed on osteosarcoma samples from patients at the time of initial biopsy, definitive surgery, and disease recurrence. The intensity and location of staining were scored. Cell-based enzyme-linked immunoadsorbent assay was performed on osteosarcoma cell lines to quantitate the level of GD2 expression.
Forty-four osteosarcoma samples were evaluated by immunohistochemistry, including 8 samples from the initial biopsy, 28 samples from the definitive surgery, and 8 samples from the time of disease recurrence. GD2 was expressed on all 44 osteosarcoma samples. Osteosarcoma tissue obtained at the time of disease recurrence demonstrated a higher intensity of staining compared with samples obtained at initial biopsy and definitive surgery (P = .016). The majority of osteosarcoma cell lines expressed GD2 at higher levels than the neuroblastoma cell line BE(2)-C.
Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma.
在过去30年中，骨肉瘤患者的生存结果一直停滞不前。用免疫疗法靶向神经节苷脂GD2（一种存在于某些肿瘤细胞表面的糖鞘脂）已使神经母细胞瘤患者的预后得到改善。在本研究中，检测了GD2在骨肉瘤中的表达模式。
对骨肉瘤患者初始活检、根治性手术和疾病复发时的样本进行免疫组织化学检测。对染色强度和位置进行评分。对骨肉瘤细胞系进行基于细胞的酶联免疫吸附测定，以定量GD2表达水平。
通过免疫组织化学评估了44例骨肉瘤样本，包括8例初始活检样本、28例根治性手术样本和8例疾病复发时的样本。所有44例骨肉瘤样本均表达GD2。与初始活检和根治性手术时获得的样本相比，疾病复发时获得的骨肉瘤组织染色强度更高（P = 0.016）。大多数骨肉瘤细胞系表达GD2的水平高于神经母细胞瘤细胞系BE(2)-C。
神经节苷脂GD2在骨肉瘤上高度表达。需要进行临床试验以评估靶向GD2对骨肉瘤患者的疗效。
